5 Chinese companies are allowed to produce Pfizer's new crown oral drug Desano for free, and Fosun Pharma is also authorized by Merck & Co.'s Molnupiravir

Pfizer Paxlovid authorization map

In the latest news, the Geneva Medicines Patent Pool (MPP) announced that it has signed agreements with 35 pharmaceutical companies to allow them to produce nirmatrelvir, one of the ingredients of Pfizer’s new crown oral drug Paxlovid

Merck Molnupiravir authorization map

It is worth noting that the new crown oral drug Molnupiravir or API has also been authorized by Merck before, among which five Chinese companies including Fosun Pharma, Borui Pharma, Langhua Pharma, Longze Pharma and Desano Pharma are listed

As a result, two companies, Fosun Pharma and Desano Pharma, have obtained the authorization of two new crown oral drugs, Molnupiravir and Pfizer Paxlovid

As soon as this news came out, the stock prices of Huahai Pharmaceutical, Fosun Pharmaceutical, Jiuzhou Pharmaceutical, and Puluo Pharmaceutical rose sharply.

About Pfizer Paxlovid Global and Chinese Markets

In the global market:

In November 2021, Pfizer announced that it had reached an agreement with the UN-backed MPP group to allow other generic drugmakers to manufacture its Covid-19 oral drug Paxlovid

Under the terms of the agreement, globally licensed and qualified generic companies will be able to offer Paxlovid's combination therapy to 95 countries, covering approximately 53% of the global population, including all low- and lower-middle-income countries in sub-Saharan Africa and Some upper-middle-income countries, as well as countries that have transitioned from lower-middle-income status to upper-middle-income status in the past five years, do not cover the Chinese market

It is worth noting that many countries and regions around the world have approved Paxlovid for emergency use or temporary authorization, and have established Paxlovid orders with Pfizer

And in the Chinese market:

On March 9, Pfizer and Sinopharm signed an agreement on the combination packaging of the new coronavirus treatment drug nematevir tablet/ritonavir tablet (ie PAXLOVID)

On March 15, in the new coronavirus pneumonia diagnosis and treatment plan (trial version 9) released in China, the specific anti-new coronavirus drug of PF-07321332/ritonavir tablet (Paxlovid) was written into the diagnosis and treatment plan

In addition, according to the Government Gazette of the Hong Kong Special Administrative Region, the first batch of oral antiviral drug Paxlovid arrived in Hong Kong on March 14, and was sent to the Hospital Authority for use on March 15